(Q35156057)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12810211%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

title

Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12810211%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12810211%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

William K Oh

series ordinal

1

1 reference

6 August 2017

publication date

1 May 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12810211%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12810211%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12810211%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12810211%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

229-234

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12810211%20AND%20SRC:MED&resulttype=core&format=json

Nomograms as predictive models

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Adjuvant and neoadjuvant therapy in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Estramustine revisited

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Dihydrotestosterone enhances transforming growth factor-beta-induced apoptosis in hormone-sensitive prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Preliminary observations of single-agent docetaxel as neoadjuvant therapy for locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Tomato products, lycopene, and prostate cancer risk

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

The role of systemic chemotherapy in the management of muscle-invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Current approaches of neoadjuvant chemotherapy in cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Adjuvant and neoadjuvant treatments for NSCLC.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Preoperative chemoradiotherapy and radical surgery for locally advanced distal rectal adenocarcinoma: pathologic findings and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Is there still a role for neoadjuvant therapy in breast cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Effect of cancer therapy on pituitary-testicular axis

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Magnetic resonance imaging of prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: correlation with histopathologic results

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Tumor cell proliferation in prostate cancer after 3 months of neoadjuvant LHRH analogue treatment is a prognostic marker of recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900019-X

7 January 2021

10.1016/S1078-1439(03)00019-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12810211%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference